期刊文献+

髓系恶性血液病8号染色体异常及其与预后的关系

原文传递
导出
摘要 目的研究髓系恶性血液病的8号染色体异常及其与预后的关系。方法 226例髓系恶性血液病初诊患者常规行染色体检查,统计患者4个疗程结束时的治疗效果,观察其与8号染色体异常的关系。结果髓系恶性血液病染色体异常率为61.50%(139/226),染色体异常病例中8号染色体异常发生率为34.53%(48/139),急性髓系白血病(AML)、骨髓增生异常综合征(MDS)和慢性髓细胞白血病(CML)三组患者均检出8号染色体三体;AML结构异常发生率最高,MDS数目异常发生率最高,CML复杂异常发生率最高,CML8号染色体异常均见于加速/急变期。8号染色体异常的患者缓解、未缓解和死亡率分别为10.42%(5/48)、52.08%(25/48)和37.5%(18/48),其中复杂异常的患者缓解率低,未缓解率和死亡率均高于数目异常和结构异常患者。结论 8号染色体异常是髓系恶性血液病中常见的染色体异常,与髓系恶性血液病预后不良有关,复杂异常的患者较数目异常和结构异常的患者疗效差。
出处 《中国优生与遗传杂志》 2010年第6期46-47,共2页 Chinese Journal of Birth Health & Heredity
  • 相关文献

参考文献8

  • 1张之南.血液病诊断及疗效标准[M].第二版.天津:天津科学技术出版社,1995.
  • 2Mitelman F, ed. An international system for human cycogenetic no- menclature. Guidelins for cancer cytogenetics [ C ]. Basl: Karger S, 1995.
  • 3Tiu R, Gondek L, et al. Clonality of the stem cell compartment during evolution of myelodysplastie syndromes and other bone marrow failure syndromes [ J ]. Leukemia ,2007,21 ( 8 ) : 1648 - 1657.
  • 4Virtaneva K, Wright FA, Tanner SM, et al. Expression profiling re- veals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics [ J ]. Proc Natl Acad Sci U S A,2001,98(3) :1124 -1129.
  • 5Maserati E, Aprili F, Vinante F, et al. Trisomy g in myelodysplasia and acute leukemia is constitutional in 15 -20% of eases[ J]. Genes Chromosomes Cancer,2002,33( 1 ) :93 - 97.
  • 6姜道滋,陈志妹,楼基余,王云贵,梁毅,金洁.1193例慢性粒细胞白血病细胞及分子遗传学分析[J].中华血液学杂志,2007,28(1):1-5. 被引量:19
  • 7徐伟来,金洁,陈志妹,楼基余,俞运彪.8号染色体三体38例临床及实验研究[J].中华医学遗传学杂志,2003,20(6):528-531. 被引量:10
  • 8李磷,刘旭平,聂玲,于明华,张悦,秦铁军,肖志坚.原发性骨髓增生异常综合征染色体核型异常特征及其预后意义的研究[J].中华血液学杂志,2009,30(4):217-222. 被引量:25

二级参考文献28

  • 1薛永权,过宇.Ph染色体阴性和少见Ph易位慢性粒细胞白血病的...[J].中华医学杂志,1993,73(4):209-212. 被引量:5
  • 2Bernasconi P, Klersy C, Boni M, et al. World Health Organiza- tion classification in combination with eytogenetic markers improves the prognostic stratification of patients with de novo primary myelo- dysplastic syndromes. Br J Haematol, 2007,137 : 193-205.
  • 3Valent P, Horny HP , Bennett JM,et al. Definitions and standards in the diagnosis and treatment of the myelodysplastie syndromes: Consensus statements and report from a working conference. Leuk Res, 2007, 31:727-736.
  • 4Vardiman JW, Harris NL, Brunning RD, et al. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 2002, 100:2292-2302.
  • 5Greenberg P, Cox C, LeBeau M, ct al. International Scoring System for Evaluating Prognosis in myelodysplastic syndromes. Blood, 1997, 89:2079-2088.
  • 6Parlier V, van Melle G, Beris P, et al. Hematologic, clinical and cytogenetic analysis in 109 patients with prirnary myelodysplastic syndrome. Prognostic significance of morphology and chromosome findings. Cancer Genet Cytogenet, 1994, 78: 219-231.
  • 7Tiu R, Gondek L, O' Keefe C, et al. Clonality of the stem cell compartment during evolution of myelodysplastic syndromes and other bone marrow failure syndromes. Leukemia, 2007, 21 : 1648- 1657.
  • 8Virtaneva K, Writht FA, Tanner SM, et al. Expression profiling reveal fundamental biological differences in acute myeloid leukemia with isolated trosomy 8 and normal cytogenetics. Proc Natl Acad Sci U S A, 2001, 98: 1124-1129.
  • 9Pfeilstocker M, Reisner R, Nosslinger T, et al. Cross-validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics. Br J Haematol, 1999, 106: 455-463.
  • 10Belli C, Acevedo S, Bengio R, et al. Detection of risk groups in myelodysplastic syndromes. A multicenter study. Haematologica, 2002, 87: 9-16.

共引文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部